BioPharmSignal logoBioPharmSignal

Biotech News

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

Assembly Biosciences (ASMB)Assembly BiosciencesClinical readout

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV)

Related news

ASMBAssembly Biosciences2026-05-22 11:00 EST

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

ASMBAssembly Biosciences2026-09-10 20:15 EST

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

AVIRAtea2026-07-14 11:00 EST

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

AVIRAtea2026-06-25 11:00 EST

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

IMNNImunon2026-06-22 20:15 EST

IMUNON to Present at the Life Sciences Investor Forum on June 25th

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

VIRIVirios Therapeutics2026-09-14 12:45 EST

Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

OGENOragenics2026-05-05 12:30 EST

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

OGENOragenics2026-04-20 13:00 EST

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

View all latest news

Assembly Biosciences

Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase...

Recent company news

ASMBAssembly Biosciences2026-09-10 20:15 EST

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

ASMBAssembly Biosciences2026-09-08 20:00 EST

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

ASMBAssembly Biosciences2026-08-13 20:00 EST

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Stock data

Close
25.34 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States